Total flavonoids from Abelmoschus manihot (L.) improve diabetes nephropathy by regulating the gut–kidney axis
Totalflavonoide aus Abelmoschus manihot (L.) verbessern die diabetische Nephropathie durch Regulation der Darm-Niere-Achse
Frontiers in Medicine · 28.01.2026 · 12
DOI: 10.3389/fmed.2025.1693643 ↗Auf einen Blick
In db/db-Mäusen senkte TFA die UACR und veränderte die Darmflora, Serum-Metaboliten und renale Genexpression. Die Autor:innen sehen die Darm-Niere-Achse als zentralen Wirkmechanismus.
Fragestellung
Welche therapeutischen Mechanismen von TFA bei diabetischer Nephropathie werden über die Darm-Niere-Achse vermittelt?
Methode
db/db-Mäuse erhielten TFA, Irbesartan oder Vehicle. UACR wurde per ELISA gemessen, die Darmflora per 16S-rRNA-Sequenzierung, Serum-Metaboliten per LC-ESI-MS/MS und die Nieren-Transkriptomik per RNA-Sequenzierung.
Ergebnisse
TFA senkte die UACR und veränderte die intestinale Flora. Es erhöhte Dietzia, Faecium, Streptococcus und Blautia sowie quercetin 3-glucuronide und n-cinnamyl glycine; Cortisol und mehrere renale Gene wurden herunterreguliert.
Schlussfolgerung der Autor:innen
TFA attenuiert die Progression der diabetischen Nephropathie über Veränderungen der Darmflora, der zirkulierenden Metaboliten und renaler Genaktivität.
Kernaussagen
- TFA senkte die UACR in db/db-Mäusen.
- Die Darmflora und Serum-Metaboliten wurden verändert.
- Renale Gene für neutrophile Signalwege wurden herunterreguliert.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Medicine, online erschienen am 28.01.2026. Verfasst von Hongmei Yu und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Qilu Medical University, Zibo, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Excellent Doctor Program of Jiangsu Province Hospital of Chinese Medicine, National Natural Science Foundation of China.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
A recent clinical study demonstrated that Huangkui capsule (with its bioactive constituents being total flavones extracted from Abelmoschus manihot (L.), TFA) combined with irbesartan provides effective therapy for type 2 diabetes (T2D) patients with diabetic nephropathy (DN).
Objective
This study aimed to elucidate the therapeutic mechanisms of TFA in DN through the modulation of the gut–kidney axis.
Methods
The db/db mice were administered TFA, irbesartan, or vehicle. Urinary albumin-creatinine ratio (UACR) was measured by the enzyme-linked immunosorbent assay (ELISA). Intestinal bacterial composition was analyzed using 16S rRNA sequencing. Serum metabolites were quantified via LC-ESI-MS/MS. Kidney transcriptomics were assessed using Illumina platform-based RNA sequencing.
Results
Administration of TFA reduced the UACR in db/db mice and significantly altered intestinal flora composition. Specifically, TFA elevated the abundance of Dietzia, Faecium, Streptococcus, and Blautia while reducing Bacteroidetes, Firmicutes, Enterobacteriaceae, Rikenellaceae, Fusivibrio, and Treponema. In serum metabolomic analysis, TFA increased the levels of quercetin 3-glucuronide and n-cinnamyl glycine but decreased cortisol concentrations. Concurrently, renal transcriptomics revealed the downregulation of key genes, including retnlg, ngp, mpo, camp, ctsg, elane, s100a8, s100a9, trem1, and mmp7, which primarily function in pathways related to neutrophil extracellular trap formation, steroid hormone biosynthesis, and cortisol synthesis/secretion. In contrast, irbesartan treatment did not significantly affect blood pressure or specific renal gene pathways in db/db mice.
Conclusion
TFA attenuates diabetic nephropathy (DN) progression through pharmacological mechanisms involving three key axes: (1) modulation of intestinal flora composition, (2) regulation of circulating metabolites, and (3) suppression of renal gene activity pathways. These findings highlight the gut–kidney axis as a central therapeutic target for TFA in DN management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Pharmacy, Qilu Medical University, Zibo, China.
- Islet Cell Senescence and Function Research Laboratory, Department of Endocrinology, Nanjing Medical University Affiliated Geriatric Hospital/Jiangsu Province Geriatric Hospital, Nanjing, China.
- Laboratory of Molecular Medicine, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
- Department of Endocrinology, Jiangsu Province Hospital of Chinese Medicine, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Förderung
- Excellent Doctor Program of Jiangsu Province Hospital of Chinese Medicine
- National Natural Science Foundation of China
Zitieren
APA
Yu, H., Liu, Y., Gu, H. F., Tang, W., & Li, N. (2026). Total flavonoids from Abelmoschus manihot (L.) improve diabetes nephropathy by regulating the gut–kidney axis. Frontiers in Medicine, 12. https://doi.org/10.3389/fmed.2025.1693643
Vancouver
Yu H, Liu Y, Gu HF, Tang W, Li N. Total flavonoids from Abelmoschus manihot (L.) improve diabetes nephropathy by regulating the gut–kidney axis. Frontiers in Medicine. 2026;12. doi:10.3389/fmed.2025.1693643
BibTeX
@article{Yu2026,
author = {Yu, Hongmei and Liu, Yuanxin and Gu, Harvest F and Tang, Wei and Li, Nan},
title = {Total flavonoids from Abelmoschus manihot (L.) improve diabetes nephropathy by regulating the gut–kidney axis},
journal = {Frontiers in Medicine},
year = {2026},
volume = {12},
doi = {10.3389/fmed.2025.1693643}
}
EUVIMED